BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Could it be said that you are As yet Utilizing Old Tires? at These 6 Tire Brands- \Step by step instructions to Pick the Best Material Organization for Your Home\
- Physicists and philosophers have long struggled to understand the nature of time: Here's why
- ‘Wicked: For Good’ streaming release — How to watch the sequel starring Ariana Grande and Cynthia Erivo
- Eleven Creations And Developments That Steered History
- Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool
- Novo and Lilly cut prices of weight-loss drugs in China
- Trump said affordability is a ‘hoax’ in his Pennsylvania speech. What do the latest numbers show?
- Research highlights potential dangers of ultra-processed foods for women under 50 regarding precancerous polyps
